[Zurück]
 
Bitte auswählen
Jahr
Details
Sprache
Sortierung
Ausgabe
neu: RTF !
 Forschungsbericht für das Jahr 2016

Department für Radiologische Diagnostik und Therapie

Klinik für Strahlenheilkunde

Robert Koch Str. 3
79106 Freiburg
Tel: 0049-761-270-9461 Fax: 0049-761-270-9472
Email anca.grosu@uniklinik-freiburg.de


Wissenschaftliche Mitarbeiterinnen und Mitarbeiter

  • Prof. Dr. med. Anca-Ligia Grosu, Ärztliche Direktorin
  • Prof. Dr. med. Thomas Brunner, Geschäftsführender Oberarzt, Geschäftsführender Oberarzt
  • Prof. Dr. med. Michael Henke, Leiter Sektion Klinische Studien
  • Dr. med. Marianne Schmucker, Geschäftsführende Oberärztin
  • Prof. Dr. Dimos Baltas, Leiter der Abt. Medizinische Physik
  • Dr. med. Karl Henne, OA
  • Dr. medic/IM Temeschburg Carmen Martini, OÄ
  • Prof. Dr. med. Ursula Nestle
  • Dr. med. Henning Schäfer, OA
  • Dr. med. Jutta Scholber, OÄ
  • Dr. med. Sonja Adebahr
  • Nico Bartl
  • Dr. med. Angelika Bilger
  • Dr. med. Martin-Immanuel Bittner
  • Stefan Bott
  • Hatice Bunea
  • Dr. med./Univ. Andrei Bunea
  • Jamina Tara Fennell
  • Dr. med. Eleni Gkika
  • Dr. med. Sarah Karnitzky
  • Dr. med. Emily Kim
  • Dr. med. Simon Kirste
  • Dr. med. Nicole Landenberger
  • Dr. med. Oliver Oehlke
  • Dr. med. Ilinca Popp
  • Nasr Salman
  • Daniel Schanne
  • Dr. med. Tanja Schimek-Jasch
  • Daniel Schnell
  • Dr. med. Andreas Thomsen
  • Dr. /VAK Moskau Natascha Volegova-Neher
  • Dr. med. Nicole Wiedenmann
  • Dr. med. Constantinos Zamboglou
  • Dr. med. Anne Sofie Zipfel
  • Amelia Cascajo Castresana
  • Dr. Maria Magdalena Fernandez Tomas
  • Dr. Mark Gainey
  • Sven Knobe
  • Dr. rer. nat. Michael Kollefrath
  • Dr. Kodor Koubar
  • Dipl. Phys. Sophie Küchler
  • Dr. Jördis Lübke
  • Dr. Sima Qamhiyeh
  • Dr. Ing. Thomas Rothe
  • Dr. rer. nat. Rolf Wiehle
  • Dr. med. Felix Heinemann, Leiter Klinische und Administrative Informatik
  • Prof. Dr. med. Gabriele Niedermann, Leiterin Sektion Strahlenbiologie
  • Dr. rer. nat. Elke Firat
  • Dr. Monika Gothwal
  • Michael Hettich
  • Shruthi Prasad
Einträge in der Rubrik "Who is Who"

Wissenschaftliche Projekte und Forschungsvorhaben


  • ALD518
  • CAO/ARO/AIO-12
  • Clonidine
  • CONKO-07
  • Elderly Studie
  • EMR100036-002 Eine offene Phase Ia / Ib-Studie mit dem DNA-PK-Inhibitor MSC2490484A in Kombination mit Strahlentherapie bei Patienten mit fortgeschrittenen soliden Tumoren
  • ESOPEC
  • F-MISO-PET
  • GLIAA - Aminosäure-PET versus MRT gesteuerte Re-Bestrahlung bei Patienten mit rezidiviertem Glioblastoma multiforme - eine randomisierte Phase II klinische Studie -
  • HERACLES
  • Hipporad MC-Studie
  • HNprädBio
  • L-AP-IS
  • L-AP-IS-Pilot
  • LARIS
  • LungArt
  • LungTech EORTC 22113-08113
  • NEOPA
    • Projektleitung: Brunner TB - Projektleitung in der Klinik f. Strahlenheilkunde
    • Laufzeit: 01.09.2013 bis 31.12.2016
    • Details zum Projekt
  • PEACE 1
  • PET-Plan-Studie
  • PORTAF
  • Radioonkologie und Bildgebung; Biologische Individualisierung im Bereich der Radioonkologie
  • SIP
  • STRIPE
  • SUMMER – Software für die multimodale Bildgebung in der Strahlentherapie
  • Tumorspezifische Immunität und Inflammation beim Malignen Melanom
  • α-RT Studie

Wissenschaftliche Publikationen

Originalarbeiten in wissenschaftlichen Fachzeitschriften:
  • Adebahr S, Schimek-Jasch T, Nestle U, Brunner TB: Oesophagus side effects related to the treatment of oesophageal cancer or radiotherapy of other thoracic malignancies. Best Pract Res Cl Ga, 2016; 30 (4): 565-580. : http://dx.doi.org/10.1016/j.bpg.2016.07.003
  • Al-Assar O, Bittner MI, Lunardi S, Stratford MR, McKenna WG, Brunner TB: The radiosensitizing effects of Nelfinavir on pancreatic cancer with and without pancreatic stellate cells. Radiother Oncol, 2016; 119 (2): 300-305. : http://dx.doi.org/10.1016/j.radonc.2016.03.024
  • Balermpas P, Rodel F, Rodel C, Krause M, Linge A, Lohaus F, Baumann M, Tinhofer I, Budach V, Gkika E, Stuschke M, Avlar M, Grosu AL, Abdollahi A, Debus J, Bayer C, Stangl S, Belka C, Pigorsch S, Multhoff G, Combs SE, Monnich D, Zips D, Fokas E: CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG). Int J Cancer, 2016; 138 (1): 171-181. : http://dx.doi.org/10.1002/ijc.29683
  • Bell EH, Chakraborty AR, Mo X, Liu Z, Shilo K, Kirste S, Stegmaier P, McNulty M, Karachaliou N, Rosell R, Bepler G, Carbone DP, Chakravarti A: SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung Cancer. Clin Cancer Res, 2016; 22 (10): 2396-2404. : http://dx.doi.org/10.1158/1078-0432.CCR-15-1468
  • Bilger A, Milanovic D, Lorenz H, Oehlke O, Urbach H, Schmucker M, Weyerbrock A, Nieder C, Grosu AL: Stereotactic fractionated radiotherapy of the resection cavity in patients with one to three brain metastases. Clin Neurol Neurosur, 2016; 142: 81-86. : http://dx.doi.org/10.1016/j.clineuro.2016.01.008
  • Bittner MI, Wiedenmann N, Bucher S, Hentschel M, Mix M, Rucker G, Weber WA, Meyer PT, Werner M, Grosu AL, Kayser G: Analysis of relation between hypoxia PET imaging and tissue-based biomarkers during head and neck radiochemotherapy. Acta Oncol, 2016; 55 (11): 1299-1304. : http://dx.doi.org/10.1080/0284186X.2016.1219046
  • Brunner TB, Nestle U, Adebahr S, Gkika E, Wiehle R, Baltas D, Grosu AL: Simultaneous integrated protection : A new concept for high-precision radiation therapy. Strahlenther Onkol, 2016; 192 (12): 886-894. : http://dx.doi.org/10.1007/s00066-016-1057-x
  • Champ CE, Francis L, Klement RJ, Dickerman R, Smith RP: Fortifying the Treatment of Prostate Cancer with Physical Activity. Prostate Cancer, 2016; 2016: 9462975-9462975. : http://dx.doi.org/10.1155/2016/9462975
  • Dolz J, Kirisli HA, Fechter T, Karnitzki S, Oehlke O, Nestle U, Vermandel M, Massoptier L: Interactive contour delineation of organs at risk in radiotherapy: Clinical evaluation on NSCLC patients. Med Phys, 2016; 43 (5): 2569-2569. : http://dx.doi.org/10.1118/1.4947484
  • Firat E, Niedermann G: FoxO proteins or loss of functional p53 maintain stemness of glioblastoma stem cells and survival after ionizing radiation plus PI3K/mTOR inhibition. Oncotarget, 2016; 7 (34): 54883-54896. : http://dx.doi.org/10.18632/oncotarget.10702
  • Glatzer M, Elicin O, Ramella S, Nestle U, Putora PM: Radio(chemo)therapy in locally advanced nonsmall cell lung cancer. Eur Respir Rev, 2016; 25 (139): 65-70. : http://dx.doi.org/10.1183/16000617.0053-2015
  • Guckenberger M, Klement RJ, Allgauer M, Andratschke N, Blanck O, Boda-Heggemann J, Dieckmann K, Duma M, Ernst I, Ganswindt U, Hass P, Henkenberens C, Holy R, Imhoff D, Kahl HK, Krempien R, Lohaus F, Nestle U, Nevinny-Stickel M, Petersen C, Semrau S, Streblow J, Wendt TG, Wittig A, Flentje M, Sterzing F: Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy. Radiother Oncol, 2016; 118 (3): 485-491. : http://dx.doi.org/10.1016/j.radonc.2015.09.008
  • Guckenberger M, Klement RJ, Allgauer M, Andratschke N, Blanck O, Boda-Heggemann J, Dieckmann K, Duma M, Ernst I, Ganswindt U, Hass P, Henkenberens C, Holy R, Imhoff D, Kahl HK, Krempien R, Lohaus F, Nestle U, Nevinny-Stickel M, Petersen C, Semrau S, Streblow J, Wendt TG, Wittig A, Flentje M, Sterzing F: Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy. Radiother Oncol, 2016; 118 (3): 485-491. : http://dx.doi.org/10.1016/j.radonc.2015.09.008
  • Hauler F, Furtado H, Jurisic M, Polanec SH, Spick C, Laprie A, Nestle U, Sabatini U, Birkfellner W: Automatic quantification of multi-modal rigid registration accuracy using feature detectors. Phys Med Biol, 2016; 61 (14): 5198-5214. : http://dx.doi.org/10.1088/0031-9155/61/14/5198
  • Hettich M, Braun F, Bartholoma MD, Schirmbeck R, Niedermann G: High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers. Theranostics, 2016; 6 (10): 1629-1640. : http://dx.doi.org/10.7150/thno.15253
  • Hettich M, Lahoti J, Prasad S, Niedermann G: Checkpoint antibodies but not T cell-recruiting diabodies effectively synergize with TIL-inducing gamma-irradiation. Cancer Res, 2016; 76 (16): 4673-4683. : http://dx.doi.org/10.1158/0008-5472.CAN-15-3451
  • Hoeppner J, Lordick F, Brunner T, Glatz T, Bronsert P, Rothling N, Schmoor C, Lorenz D, Ell C, Hopt UT, Siewert JR: ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286). Bmc Cancer, 2016; 16 (online): 503. : http://dx.doi.org/10.1186/s12885-016-2564-y
  • Jehmlich N, Stegmaier P, Golatowski C, Salazar MG, Rischke C, Henke M, Volker U: Proteome data of whole saliva which are associated with development of oral mucositis in head and neck cancer patients undergoing radiotherapy. Data Brief, 2016; 8: 501-505. : http://dx.doi.org/10.1016/j.dib.2016.05.053
  • Jehmlich N, Stegmaier P, Golatowski C, Salazar MG, Rischke C, Henke M, Volker U: Proteome data of whole saliva which are associated with development of oral mucositis in head and neck cancer patients undergoing radiotherapy. Data Brief, 2016; 8: 501-505. : http://dx.doi.org/10.1016/j.dib.2016.05.053
  • Jehmlich N, Stegmaier P, Golatowski C, Salazar MG, Rischke C, Henke M, Volker U: Proteome data of whole saliva which are associated with development of oral mucositis in head and neck cancer patients undergoing radiotherapy. Data in Brief, 2016; 8: 501-505. : http://dx.doi.org/10.1016/j.dib.2016.05.053
  • Jehmlich N, Stegmaier P, Golatowski C, Salazar MG, Rischke C, Henke M, Volker U: Proteome data of whole saliva which are associated with development of oral mucositis in head and neck cancer patients undergoing radiotherapy. Data Brief, 2016; 8: 501-505. : http://dx.doi.org/10.1016/j.dib.2016.05.053
  • Jing H, Weidensteiner C, Reichardt W, Gaedicke S, Zhu X, Grosu AL, Kobayashi H, Niedermann G: Imaging and Selective Elimination of Glioblastoma Stem Cells with Theranostic Near-Infrared-Labeled CD133-Specific Antibodies. Theranostics, 2016; 6 (6): 862-874. : http://dx.doi.org/10.7150/thno.12890
  • Kirste S, Trautsch H, Messmer MB, Wiehle R, Rischke HC, Momm F, Grosu AL, Brunner TB: Abdominal stereotactic body radiotherapy: local control and correlaton to biologically equivalent dose OMICS J Radiol, 2016; 5 (2): 1-7.
  • Klement RJ, Allgauer M, Andratschke N, Blanck O, Boda-Heggemann J, Dieckmann K, Duma M, Ernst I, Flentje M, Ganswindt U, Hass P, Henkenberens C, Imhoff D, Kahl HK, Krempien R, Lohaus F, Nestle U, Nevinny-Stickel M, Petersen C, Schmitt V, Semrau S, Sterzing F, Streblow J, Wendt TG, Wittig A, Guckenberger M: Bayesian Cure Rate Modeling of Local Tumor Control: Evaluation in Stereotactic Body Radiation Therapy for Pulmonary Metastases. Int J Radiat Oncol, 2016; 94 (4): 841-849. : http://dx.doi.org/10.1016/j.ijrobp.2015.12.004
  • Klement RJ, Allgauer M, Andratschke N, Blanck O, Boda-Heggemann J, Dieckmann K, Duma M, Ernst I, Flentje M, Ganswindt U, Hass P, Henkenberens C, Imhoff D, Kahl HK, Krempien R, Lohaus F, Nestle U, Nevinny-Stickel M, Petersen C, Schmitt V, Semrau S, Sterzing F, Streblow J, Wendt TG, Wittig A, Guckenberger M: Bayesian Cure Rate Modeling of Local Tumor Control: Evaluation in Stereotactic Body Radiation Therapy for Pulmonary Metastases. Int J Radiat Oncol, 2016; 94 (4): 841-849. : http://dx.doi.org/10.1016/j.ijrobp.2015.12.004
  • Klement RJ, Belderbos J, Grills I, Werner-Wasik M, Hope A, Giuliani M, Ye H, Sonke JJ, Peulen H, Guckenberger M: Prediction of Early Death in Patients with Early-Stage NSCLC-Can We Select Patients without a Potential Benefit of SBRT as a Curative Treatment Approach? J Thorac Oncol, 2016; 11 (7): 1132-1139. : http://dx.doi.org/10.1016/j.jtho.2016.03.016
  • Klement RJ, Champ CE, Otto C, Kammerer U: Anti-Tumor Effects of Ketogenic Diets in Mice: A Meta-Analysis. Plos One, 2016; 11 (5): e0155050-e0155050. : http://dx.doi.org/10.1371/journal.pone.0155050
  • Klement RJ, Fink MK: Dietary and pharmacological modification of the insulin/IGF-1 system: exploiting the full repertoire against cancer. Oncogenesis, 2016; 5: e193-e193. : http://dx.doi.org/10.1038/oncsis.2016.2
  • Klement RJ, Sweeney RA: Impact of a ketogenic diet intervention during radiotherapy on body composition: II. Protocol of a randomised phase I study (KETOCOMP). Clin Nutr ESPEN, 2016; 12: e1-e6. : http://dx.doi.org/10.1016/j.clnesp.2015.11.001
  • Klement RJ, Sweeney RA: Impact of a ketogenic diet intervention during radiotherapy on body composition: I. Initial clinical experience with six prospectively studied patients. BMC Res Notes, 2016; 9: 143-143. : http://dx.doi.org/10.1186/s13104-016-1959-9
  • Krönig M, Nanko N, Drendel V, Werner M, Schultze-Seemann W, Grosu AL, Jilg AC: Single punch, double biopsy. Springerplus, 2016; 5 (1) (online): 1456. : http://dx.doi.org/10.1186/s40064-016-3141-1
  • Lambers K, Hasenburg A, Stickeler E, Gitsch G, Grosu AL, Henne K, Farthmann J: Customized treatment of recurrent gynaecological cancer-the need for intraoperative radiation therapy. Eur J Gynaecol Oncol, 2016; 37 (1): 48-52.
  • Lambrecht M, Melidis C, Sonke JJ, Adebahr S, Boellaard R, Verheij M, Guckenberger M, Nestle U, Hurkmans C: Lungtech, a phase II EORTC trial of SBRT for centrally located lung tumours - a clinical physics perspective. Radiat Oncol, 2016; 11 (1): 7-7. : http://dx.doi.org/10.1186/s13014-015-0567-5
  • Linge A, Lock S, Gudziol V, Nowak A, Lohaus F, von Neubeck C, Jutz M, Abdollahi A, Debus J, Tinhofer I, Budach V, Sak A, Stuschke M, Balermpas P, Rodel C, Avlar M, Grosu AL, Bayer C, Belka C, Pigorsch S, Combs SE, Welz S, Zips D, Buchholz F, Aust DE, Baretton GB, Thames H, Dubrovska A, Alsner J, Overgaard J, Baumann M, Krause M: Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(−) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG. Clin Cancer Res, 2016; 22 (11): 2639-2649. : http://dx.doi.org/10.1158/1078-0432.CCR-15-1990
  • Linge A, Lohaus F, Lock S, Nowak A, Gudziol V, Valentini C, von Neubeck C, Jutz M, Tinhofer I, Budach V, Sak A, Stuschke M, Balermpas P, Rodel C, Grosu AL, Abdollahi A, Debus J, Ganswindt U, Belka C, Pigorsch S, Combs SE, Monnich D, Zips D, Buchholz F, Aust DE, Baretton GB, Thames HD, Dubrovska A, Alsner J, Overgaard J, Krause M, Baumann M: HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Radiother Oncol, 2016; 121 (3): 364-373. : http://dx.doi.org/10.1016/j.radonc.2016.11.008
  • Nieder C, Andratschke NH, Grosu AL: Re-irradiation for Recurrent Primary Brain Tumors. Anticancer Res, 2016; 36 (10): 4985-4995.
  • Nieder C, Hintz M, Grosu AL: Predicted survival in patients with brain metastases from colorectal cancer: Is a current nomogram helpful? Clin Neurol Neurosur, 2016; 143: 107-110. : http://dx.doi.org/10.1016/j.clineuro.2016.02.022
  • Nieder C, Hintz M, Grosu AL: Colorectal cancer metastatic to the brain: analysis of prognostic factors and impact of KRAS mutations on presentation and outcome. Clin Transl Oncol, 2016; 18 (1): 88-92. : http://dx.doi.org/10.1007/s12094-015-1340-9
  • Nieder C, Langendijk JA, Guckenberger M, Grosu AL: Prospective randomized clinical studies involving reirradiation : Lessons learned. Strahlenther Onkol, 2016; 192 (10): 679-686. : http://dx.doi.org/10.1007/s00066-016-1024-6
  • Niyazi M, Brada M, Chalmers AJ, Combs SE, Erridge SC, Fiorentino A, Grosu AL, Lagerwaard FJ, Minniti G, Mirimanoff RO, Ricardi U, Short SC, Weber DC, Belka C: ESTRO-ACROP guideline "target delineation of glioblastomas". Radiother Oncol, 2016; 118 (1): 35-42. : http://dx.doi.org/10.1016/j.radonc.2015.12.003
  • Oehlke O, Mix M, Graf E, Schimek-Jasch T, Nestle U, Gotz I, Schneider-Fuchs S, Weyerbrock A, Mader I, Baumert BG, Short SC, Meyer PT, Weber WA, Grosu AL: Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) - protocol of a randomized phase II trial (NOA 10/ARO 2013-1). Bmc Cancer, 2016; 16 (1) (online): 769. : http://dx.doi.org/10.1186/s12885-016-2806-z
  • Osterberg N, Ferrara N, Vacher J, Gaedicke S, Niedermann G, Weyerbrock A, Doostkam S, Schaefer HE, Plate KH, Machein MR: Decrease of VEGF-A in myeloid cells attenuates glioma progression and prolongs survival in an experimental glioma model. Neuro-oncology, 2016; 18 (7): 939-949. : http://dx.doi.org/10.1093/neuonc/now005
  • Panje C, Andratschke N, Brunner TB, Niyazi M, Guckenberger M: Stereotactic body radiotherapy for renal cell cancer and pancreatic cancer : Literature review and practice recommendations of the DEGRO Working Group on Stereotactic Radiotherapy. Strahlenther Onkol, 2016; 192 (12): 875-885. : http://dx.doi.org/10.1007/s00066-016-1053-1
  • Popp I, Grosu AL, Niedermann G, Duda DG: Immune modulation by hypofractionated stereotactic radiation therapy: Therapeutic implications. Radiother Oncol, 2016; 120 (2): 185-194. : http://dx.doi.org/10.1016/j.radonc.2016.07.013
  • Popp I, Grosu AL, Niedermann G, Duda DG: Immune modulation by hypofractionated stereotactic radiation therapy: Therapeutic implications. Radiother Oncol, 2016; 120 (2): 185-194. : http://dx.doi.org/10.1016/j.radonc.2016.07.013
  • Ramkumar A, Dolz J, Kirisli HA, Adebahr S, Schimek-Jasch T, Nestle U, Massoptier L, Varga E, Stappers PJ, Niessen WJ, Song Y: User Interaction in Semi-Automatic Segmentation of Organs at Risk: a Case Study in Radiotherapy. J Digit Imaging, 2016; 29 (2): 264-277. : http://dx.doi.org/10.1007/s10278-015-9839-8
  • Rieber J, Streblow J, Uhlmann L, Flentje M, Duma M, Ernst I, Blanck O, Wittig A, Boda-Heggemann J, Krempien R, Lohaus F, Klass ND, Eble MJ, Imhoff D, Kahl H, Petersen C, Gerum S, Henkenberens C, Adebahr S, Hass P, Schrade E, Wendt TG, Hildebrandt G, Andratschke N, Sterzing F, Guckenberger M: Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy". Lung Cancer, 2016; 97: 51-58. : http://dx.doi.org/10.1016/j.lungcan.2016.04.012
  • Rischke HC, Eiberger AK, Volegova-Neher N, Henne K, Krauss T, Grosu AL, Jilg CA: PET/CT and MRI directed extended salvage radiotherapy in recurrent prostate cancer with lymph node metastases. Adv Med Sci-poland, 2016; 61 (2): 212-218. : http://dx.doi.org/10.1016/j.advms.2016.01.003
  • Roesch J, Panje C, Sterzing F, Mantel F, Nestle U, Andratschke N, Guckenberger M: SBRT for centrally localized NSCLC - What is too central? Radiat Oncol, 2016; 11 (1) (online): 157. : http://dx.doi.org/10.1186/s13014-016-0732-5
  • Schaefer A, Vermandel M, Baillet C, Dewalle-Vignion AS, Modzelewski R, Vera P, Massoptier L, Parcq C, Gibon D, Fechter T, Nemer U, Gardin I, Nestle U: Impact of consensus contours from multiple PET segmentation methods on the accuracy of functional volume delineation. Eur J Nucl Med Mol I, 2016; 43: 911-924. : http://dx.doi.org/10.1007/s00259-015-3239-7
  • Schlachter M, Fechter T, Jurisic M, Schimek-Jasch T, Oehlke O, Adebahr S, Birkfellner W, Nestle U, Buhler K: Visualization of Deformable Image Registration Quality using Local Image Dissimilarity. Ieee T Med Imaging, 2016; 35 (10): 2319-2328. : http://dx.doi.org/10.1109/TMI.2016.2560942
  • Tinhofer I, Budach V, Saki M, Konschak R, Niehr F, Johrens K, Weichert W, Linge A, Lohaus F, Krause M, Neumann K, Endris V, Sak A, Stuschke M, Balermpas P, Rodel C, Avlar M, Grosu AL, Abdollahi A, Debus J, Belka C, Pigorsch S, Combs SE, Monnich D, Zips D, Baumann M: Targeted next-generation sequencing of locally advanced squamous cell carcinomas of the head and neck reveals druggable targets for improving adjuvant chemoradiation. Eur J Cancer, 2016; 57: 78-86. : http://dx.doi.org/10.1016/j.ejca.2016.01.003
  • Wilson JM, Fokas E, Dutton SJ, Patel N, Hawkins MA, Eccles C, Chu KY, Durrant L, Abraham AG, Partridge M, Woodward M, O'Neill E, Maughan T, McKenna WG, Mukherjee S, Brunner TB: ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer. Radiother Oncol, 2016; 119 (2): 306-311. : http://dx.doi.org/10.1016/j.radonc.2016.03.021
  • Zamboglou C *, Schiller F *, Fechter T *, Wieser G, Jilg C, Chirindel A, Salman N, Drendel V, Werner M, Mix M, Meyer P *, Grosu AL *: 68GA-HBED-CC-PSMA PET/CT Versus Histopathology In Primary Localized Prostate Cancer: A Voxel-Wise Comparison. Theranostics, 2016; 6 (10): 1619-1628. : http://dx.doi.org/10.7150/thno.15344
  • Zamboglou C *, Wieser G *, Hennies S, Rempel I, Kirste S, Soschynski M, Rischke HC, Fechter T, Jilg CA, Langer M, Meyer PT, Bock M *, Grosu AL *: MRI versus 68Ga-PSMA PET/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancer. Eur J Nucl Med Mol I, 2016; 43: 889-897. : http://dx.doi.org/10.1007/s00259-015-3257-5
Reviews/Übersichtsartikel in wissenschaftlichen Fachzeitschriften:
Fallbeispiele:
  • Zamboglou C, Rischke HC, Meyer PT, Knobe S, Volgeova-Neher N, Kollefrath M, Jilg CA, Grosu AL, Baltas D, Kroenig M: Single fraction multimodal image guided focal salvage high-dose-rate brachytherapy for recurrent prostate cancer. J Contemp Brachyther, 2016; 8 (3): 241-248. : http://dx.doi.org/10.5114/jcb.2016.61067
Kurzbeiträge / short communications:
  • Bennett CL, Lai SY, Sartor O, Georgantopoulos P, Hrushesky WJ, Henke M, Armitage JO: Consensus on the Existence of Functional Erythropoietin Receptors on Cancer Cells. Jama-j Am Med Assoc, 2016; 2 (1): 134-136. : http://dx.doi.org/10.1001/jamaoncol.2015.3940
Vorträge:
  • Grosu AL: Molekulare Bildgebung zur Strahlentherapieplanung - Konzepte 2016 (32. Deutscher Krebskongress/Berlin).
  • Grosu AL: Bestrahlungsplanung mit PET oder MRT oder beidem? 2016 (32. Deutscher Krebskongress/Berlin).
  • Grosu AL: Was muss bestrahlt werden: Personalisierte Zielvolumina 2016 (32. Deutscher Krebskongress/Berlin).
  • Grosu AL: Bildgebung für Strahlentherapie bei Gliomen 2016 (60. Wissenschaftliche Jahrestagung der DGKN/Düsseldorf).
  • Grosu AL: Imaging for radiation treatment planning 2016 (Projetct meeting on functional imaging in radiation therapy/Stockholm/Karolinska I.).
  • Grosu AL: PET and MRI for radiation treatment planning in head and neck tumors with extension to the anterior base of skull 2016 (21th congess of the European Skull Base Society/Berlin).
  • Grosu AL: Stereotaktische Strahlentherapie / Radiochirurgie bei Oligometastasen 2016 (36. Jahrestagung der Dt. Gesellschaft für Senologie).
  • Grosu AL: Schonende und präzise Strahlentherapie im Kopfbereich - neue Entwicklungen 2016 (Welthirntumortag/UKL Freiburg).
  • Grosu AL: Biological tumor target concepts in radiotherapy 2016 (Ruhr Talks/Gelsenkirchen).
  • Grosu AL: Hippocampusschonung bei GHB von Hirnmetastasen 2016 (DEGRO 2016/Mannheim).
  • Grosu AL: PSMA-PET-CT und 3T_MRT für die GTV-Definition des PCA 2016 (DEGRO 2016/Mannheim).
  • Heinemann F: Digitale Akte - Vorteile, Nachteile und gesetzliche Hürden 2016 (II. Bamberger Innovationstage).
  • Heinemann F: Digitale Strahlentherapie 2016 (22. Jahrestagung der Deutschen Gesellschaft für Radioonkologie - DEGRO / Mannheim).
  • Niedermann G: Quantitative Pharmacokinetic PET Imaging of a T Cell-Dependent Bispecific Diabody for the Treatment of Solid Tumors 2016 (DGN Jahrestagung/Dresden).
  • Niedermann G: Imaging and selective elimination of glioblastoma stem cells with theranostic near-infrared-labeled CD133-specific antibodies 2016 (11th European Molecular Imaging Meeting EMIM/Utrecht/Netherlands).
  • Niedermann G: Quantitative Pharmacokinetic PET Imaging of a T Cell-Dependent Bispecific Diabody for the Treatment of Solid Tumors 2016 (11th European Molecular Imaging Meeting (EMIM/Utrecht (Netherlands)).
  • Niedermann G: FoxO proteins and non-functional p53 determine stemness and radiosensitivity of GBM-stem cells 2016 (ESTRO 2016 /Turin (Italy)).
  • Niedermann G: Non-invasive imaging of the PD-1/PD-L1 checkpoint in naive mice and after combined radioimmunotherapy 2016 (ESTRO /Turin (Italy)).
  • Niedermann G: Non-invasive imaging of the PD-1/PD-L1 checkpoint in naive and irradiated tumor-bearth mice 2016 (DEGRO 2016/Mannheim).
  • Niedermann G: Role of FoxO proteins and non-functional p53 for stemness and radiosensitivity of GBM-stem cells 2016 (DEGRO 2016/Mannheim).
Sonstige Publikationen:

Besondere wissenschaftliche Aktivitäten
Stipendien:
  • Daniel Schanne: Stiftung - Alexander v. Humboldt Feodor Lynen-Forschungsstipendium Alexander v. Humboldt Stiftung für einen wissenschaftlichen Aufenthalt in Harvard - Edwin L. Steele Laboratory Department of Radiation Oncology Harvard Medical School/Massachusetts General Hospital, Boston, USA, 01.09.2014 bis 31.08.2016.
  • Dr. med. Martin-Immanuel Bittner: Stipendium - Rhodes Trust wissenschaftlicher Aufenthalt an der Oxford University, 01.10.2015 bis 30.09.2016.
  • Montserrat Carles: Forschungsstipendium - Universitätsklinik La Fe; Valencia/Spanien, 01.07.2015 bis 30.06.2017.
  • Xuawei Zhang: Stipendium "Chinese National Fund" Teilprojekt - Radiosensitization of GBM stem cells, 01.11.2015 bis 31.10.2016.
Vorsitze und Sprechertätigkeiten:
  • Prof. Dr. med. Anca-L.Grosu, Heinemann F, Röhner F, Schmucker M: Elektronische Krankenakte in der Strahlenheilkunde, DEGRO Ausschuss, seit 09.07.2009.
  • Prof. Dr. med. Anca-L. Grosu: Vorstandsvorsitzende der Hanns-Langendorf-Stiftung, seit 2010.
  • Prof. Dr. med. Anca-Ligia Grosu: Vorstandsmitglied der Deutschen Neuroonkologischen Arbeitsgruppe (NOA), seit 2011.
  • Prof. Dr. med. Anca-Ligia Grosu: Mitglied des unabhängigen Expertengremiums der Deutschen Gesellschaft für Radioonkologie (DEGRO), seit 2011.
  • Prof. Dr. med. Anca-Ligia Grosu: Mitglied der Arbeitsgemeinschaft Radiologische Onkologie (ARO), seit 2011.
  • Prof. Dr. med. Anca-Ligia Grosu: Mitglied des Geschäftsführenden Vorstands des Comprehensive Cancer Centers, Universitätsklinikum Freiburg (CCCF), seit 2012.
  • Prof. Dr. med. Anca-Ligia Grosu: Mitglied im Beirat des Comprehensive Cancer Centers Graz (CCC Graz), Österreich, seit 2014.
  • Prof. Dr. med. Anca-Ligia Grosu: Stellvertretende Vorsitzende des Deutschen Konsortiums für Translationale Krebsmedizin, Universitätsklinikum Freiburg (DKTK Partnerstandort Freiburg) , seit 2015.
  • Prof. Dr. med. Anca-Ligia Grosu: Mitglied im Senat der Albert-Ludwigs-Universität Freiburg , seit 2015.
  • Prof. Dr. med. Anca-Ligia Grosu: Mitglied der Redaktionsleitung der Fachzeitschrift "Radiotherapy and Oncology" (The Green Journal), seit 2015.
  • Prof. Dr. med. Anca-Ligia Grosu: Mitglied der Redaktion der Fachzeitschrift "Strahlentherapie und Onkologie", seit 2016.
  • Prof. Dr. med. Anca-Ligia Grosu: Mitglied der Redaktionsleitung der Fachzeitschrift "Physics and Imaging in Radiation Oncology", seit 01.08.2016.
  • Prof. Dr. med. Ursula Nestle: Vorsitzende des Ausschusses "Strahlenschutz in der Medizin" Strahlenschutzkommission , seit 2015.
Veranstaltung:
  • Prof. Dr. med. Anca-Ligia Grosu: ESTRO 2016: Radiobiology5: Imaging and molecular biomarkers in radiation oncology, ESTRO 2016, 02.05.2016.

Abschlussarbeiten